Aptose lands $8.5M Hanmi loan to fund Tuspetinib AML trials

Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.

Rhea-AI Filing Summary

Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.

Key terms:

• Facility available in up to 5 advances (≤US$2.5 m each) through 31 Dec 2025; non-revolving.
• Interest: 6% fixed; balloon repayment of all principal and accrued interest on 31 Aug 2028.
• Secured by first-ranking liens on all present and after-acquired property of Aptose and guaranteed by subsidiaries.
• Purpose limited to continued clinical development and operating costs related to Tuspetinib, an AML therapy.
• Contains customary covenants and default provisions; any re-borrowings prohibited.

The filing also triggers Item 2.03 for creation of a direct financial obligation. The debt adds leverage but supplies non-dilutive capital for ongoing trials.

Positive

• US$8.5 million non-dilutive debt financing provides immediate liquidity to advance Tuspetinib clinical program.
• Favorable 6% fixed interest and long maturity to 2028 defer cash outflows during development phase.

Negative

• Loan is secured by a blanket first-ranking lien on all assets and subsidiary guarantees, limiting future borrowing flexibility.
• Single balloon repayment of principal and interest due 31 Aug 2028 introduces refinancing and liquidity risk.

Insights

Financial Analyst

US$8.5m loan adds non-dilutive cash, modest 6% cost, funding Tuspetinib; positive liquidity uptick.

The structured facility injects up to US$8.5 million over six months, extending the cash runway for Tuspetinib's frontline AML program without issuing equity. The 6% fixed rate is favorable for a pre-revenue biotech and the single bullet maturity in 2028 defers cash outflows during pivotal trials. Because it is non-revolving and capped at five draws, management must still manage working capital tightly, but the incremental liquidity materially reduces near-term financing risk. Overall, the deal is strategically accretive, buying time to generate clinical data that could catalyze higher-value financing later.

Risk Analyst

Liquidity gain offset by blanket lien and covenant stack; net neutral.

While the loan supplies needed funds, Hanmi receives a first-ranking security interest over all assets and unlimited subsidiary guarantees, effectively priming any future creditors. The non-revolving structure means drawn cash cannot be re-borrowed once repaid, and a single US$8.5 million balloon must be refinanced by 2028—potentially when additional capital is required for commercialization. Restrictive covenants on mergers, additional debt, and business changes may constrain strategic flexibility. Absent revenue generation, the leverage increases default risk if clinical outcomes disappoint. These offset the short-term liquidity benefit, making the impact broadly neutral from a risk standpoint.

8-K Event Classification

3 items: 1.01, 2.03, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much funding did APTO secure under the new loan agreement?

The facility allows up to US$8.5 million in aggregate principal, disbursed in no more than five advances.

What interest rate and maturity apply to APTO's Hanmi loan?

Each advance accrues 6% fixed annual interest; all principal, interest and fees are payable in full on August 31, 2028.

What will APTO use the Hanmi financing for?

Proceeds are restricted to Tuspetinib business operations, related accounts payable and general corporate uses tied to the TUS program, unless Hanmi approves otherwise.

Does the Hanmi loan dilute APTO shareholders?

No; the agreement is debt-based and involves no equity issuance or convertible features.

What collateral secures Hanmi's loan to APTO?

Hanmi holds a first-ranking security interest over all present and after-acquired personal property of Aptose and its subsidiaries, which also provide unlimited guarantees.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 07:30 AM Learn about SEC filing dates

false 0000882361 0000882361 2025-06-20 2025-06-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2025

APTOSE BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6

Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

On June 20, 2025, Aptose Biosciences Inc., as borrower (the “Company”), announced that it had entered into a loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd., as lender (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5 million (the “Facility”), administered through multiple advances for the purpose of continued clinical development of a Tuspetinib (“TUS”) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), accounts payable with respect of the Company’s TUS related business operations, and general corporate purposes reasonably related to the Company’s TUS related business operations.

The Facility may be advanced in one or more (but not more than five (5) advances) until December 31, 2025. The Facility is a non-revolving facility, and amounts repaid thereunder may not be reborrowed. No single advance shall be for an amount in excess of US$2,500,000.

The aggregate principal amount of all advances and all accrued and unpaid interest and fees together with all other obligations under the Loan Agreement will be repayable by the Company in full on August 31, 2028. Any unpaid principal amount with respect to each advance shall accrue interest a six percent (6%) per annum.

The proceeds from borrowings under the Loan Agreement will be used by the Company to fund its: (a) TUS related business operations, (b) accounts payable with respect of the Company’s TUS related business operations, and (c) general corporate purposes reasonably related to the Company’s TUS related business operations, in each case, unless the Company has obtained the prior written approval of Hanmi.

The Loan Agreement also contains customary affirmative and negative covenants with respect to the Company, including, among other things, compliance with laws, no change of business, no merger and maintenance of corporate existence, maintenance of insurance, restrictions on the incurrence of loans and guarantees, and other customary covenants. These covenants are subject to a number of limitations and exceptions as provided in the Loan Agreement.

The Company’s obligations under the Loan Agreement are secured by a first ranking security interest over all present and after acquired personal property of the Company and unlimited guarantees by, and first ranking security over all present and after acquired personal property of each of Aptose’s subsidiaries.

Additionally, the Loan Agreement contains customary events of default, insolvency, cessation of production, material adverse effect as well as remedies for credit facilities of this nature.

The description of the Loan Agreement contained in this Item 1.01 is qualified in its entirety by reference to the complete text of the Loan Agreement, a copy of which is filed herewith as Exhibit 10.1, to this Current Report on Form 8-K. 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information related to the Loan Agreement set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1*		2025 Loan Agreement, dated June 18, 2025, between Hanmi Pharmaceutical Co., Ltd., the Company, Aptose Biosciences U.S. Inc. and NuChem Pharmaceuticals Inc.
104		Cover Page Interactive Data File (formatted as Inline XBRL).

* Certain portions of this exhibit have been redacted pursuant to Regulation S-K, Item 601(a)(6) and Item 601(b)(2)(ii). This exhibit excludes certain immaterial schedules and exhibits pursuant to the provisions of Regulation S-K, Item 601(a)(5). A copy of any of the omitted information, schedules and exhibits pursuant to Regulation S-K, Item 601(a)(5), Item 601(a)(6) and Item 601(b)(2)(ii), as applicable, will be furnished to the Securities and Exchange Commission upon request.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: June 26, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer